HK1128924A1 - Sparc-derived cancer rejection antigen peptide and pharmaceutical comprising the same sparc - Google Patents

Sparc-derived cancer rejection antigen peptide and pharmaceutical comprising the same sparc

Info

Publication number
HK1128924A1
HK1128924A1 HK09105810A HK09105810A HK1128924A1 HK 1128924 A1 HK1128924 A1 HK 1128924A1 HK 09105810 A HK09105810 A HK 09105810A HK 09105810 A HK09105810 A HK 09105810A HK 1128924 A1 HK1128924 A1 HK 1128924A1
Authority
HK
Hong Kong
Prior art keywords
sparc
peptide
pharmaceutical
cells
acid sequence
Prior art date
Application number
HK09105810A
Other languages
English (en)
Inventor
Yasuharu Nishimura
Yoshiaki Ikuta
Shuichi Nakatsuru
Original Assignee
Onco Therapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onco Therapy Science Inc filed Critical Onco Therapy Science Inc
Publication of HK1128924A1 publication Critical patent/HK1128924A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK09105810A 2006-06-16 2009-06-29 Sparc-derived cancer rejection antigen peptide and pharmaceutical comprising the same sparc HK1128924A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006167724 2006-06-16
PCT/JP2007/062117 WO2007145318A1 (ja) 2006-06-16 2007-06-15 Sparc由来の癌拒絶抗原ペプチド及びこれを含む医薬

Publications (1)

Publication Number Publication Date
HK1128924A1 true HK1128924A1 (en) 2009-11-13

Family

ID=38831831

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09105810A HK1128924A1 (en) 2006-06-16 2009-06-29 Sparc-derived cancer rejection antigen peptide and pharmaceutical comprising the same sparc

Country Status (15)

Country Link
US (3) US8053557B2 (zh)
EP (1) EP2030984B1 (zh)
JP (1) JP5150849B2 (zh)
KR (1) KR101408173B1 (zh)
CN (3) CN103435683B (zh)
AT (1) ATE509096T1 (zh)
AU (1) AU2007259667B2 (zh)
BR (1) BRPI0713731B8 (zh)
CA (1) CA2655361C (zh)
ES (1) ES2365077T3 (zh)
HK (1) HK1128924A1 (zh)
IL (1) IL195831A (zh)
MX (1) MX2008015939A (zh)
RU (1) RU2451521C2 (zh)
WO (1) WO2007145318A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007018199A1 (ja) 2005-08-09 2007-02-15 Kumamoto University HLA-A2陽性者用glypican-3(GPC3)由来癌拒絶抗原ペプチド及びこれを含む医薬
CN103435683B (zh) 2006-06-16 2016-02-03 肿瘤疗法·科学股份有限公司 来自sparc的癌排斥抗原肽以及含有该肽的药物
TWI596109B (zh) * 2007-02-21 2017-08-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
TWI543767B (zh) * 2008-08-19 2016-08-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
JP5580329B2 (ja) * 2008-12-05 2014-08-27 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー Ｓｐａｒｃ結合ペプチド及びその使用
TWI507204B (zh) * 2009-05-26 2015-11-11 Oncotherapy Science Inc Ｃｄｃ４５ｌ胜肽與含此胜肽之疫苗
CN102576016A (zh) * 2009-09-18 2012-07-11 阿布拉西斯生物科学有限责任公司 Sparc微环境标签在癌症治疗中的应用
KR20130010477A (ko) * 2010-03-11 2013-01-28 아브락시스 바이오사이언스, 엘엘씨 Ｓｐａｒｃ 혈관형성 영역과 사용방법
US9193782B2 (en) 2010-06-03 2015-11-24 Abraxis Bioscience, Llc Use of the SPARC microenvironment signature in the treatment of cancer
KR101988895B1 (ko) 2011-05-19 2019-06-13 도레이 카부시키가이샤 면역 유도제
US11191804B2 (en) * 2018-01-09 2021-12-07 Fujita Academy Cytocidal agent
WO2019160099A1 (ja) * 2018-02-15 2019-08-22 大塚製薬株式会社 がん抗原ペプチド

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2166368T3 (es) * 1993-12-24 2002-04-16 Merck Patent Gmbh Inmunoconjugados.
JP2000023673A (ja) * 1998-07-13 2000-01-25 Ajinomoto Co Inc ヒト胃癌抗原遺伝子および胃癌抗原蛋白質
AU2001266787A1 (en) * 2000-06-07 2002-01-08 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
JP2005508141A (ja) * 2001-05-25 2005-03-31 セローノ ジェネティクス インスティテュート ソシエテ アニニム ヒトｃＤＮＡおよびタンパク質、ならびにそれらの使用
DK1536006T3 (da) * 2002-08-30 2011-10-17 Medinet Co Ltd Cancerantigener og anvendelse deraf
US20060204960A1 (en) * 2002-10-25 2006-09-14 Oncotherapy Science, Inc. Method for diagnosing diffuse-type gastric cancers
JP2004303688A (ja) 2003-04-01 2004-10-28 Matsushita Electric Works Ltd 放電灯点灯装置
EP1684076B1 (en) * 2003-10-29 2008-12-31 Kumamoto Technology & Industry Foundation Diagnostic method for malignant melanoma
WO2006043362A1 (ja) * 2004-10-19 2006-04-27 Kumamoto University 悪性黒色腫（メラノーマ）の新規な診断キット
WO2007018199A1 (ja) * 2005-08-09 2007-02-15 Kumamoto University HLA-A2陽性者用glypican-3(GPC3)由来癌拒絶抗原ペプチド及びこれを含む医薬
CN103435683B (zh) 2006-06-16 2016-02-03 肿瘤疗法·科学股份有限公司 来自sparc的癌排斥抗原肽以及含有该肽的药物

Also Published As

Publication number Publication date
US9120842B2 (en) 2015-09-01
IL195831A (en) 2012-05-31
CN103435683B (zh) 2016-02-03
CA2655361A1 (en) 2007-12-21
CA2655361C (en) 2014-10-07
BRPI0713731B8 (pt) 2021-05-25
RU2451521C2 (ru) 2012-05-27
CN101472943A (zh) 2009-07-01
BRPI0713731A2 (pt) 2012-10-30
KR20090038873A (ko) 2009-04-21
US8470968B2 (en) 2013-06-25
EP2030984A1 (en) 2009-03-04
KR101408173B1 (ko) 2014-06-16
CN101472943B (zh) 2013-07-17
EP2030984B1 (en) 2011-05-11
ES2365077T3 (es) 2011-09-21
BRPI0713731B1 (pt) 2019-09-24
US20100152421A1 (en) 2010-06-17
JP5150849B2 (ja) 2013-02-27
CN105418751A (zh) 2016-03-23
MX2008015939A (es) 2009-02-11
AU2007259667B2 (en) 2012-06-14
CN103435683A (zh) 2013-12-11
JPWO2007145318A1 (ja) 2009-11-12
WO2007145318A1 (ja) 2007-12-21
AU2007259667A1 (en) 2007-12-21
RU2009101191A (ru) 2010-08-10
US8053557B2 (en) 2011-11-08
CN105418751B (zh) 2019-03-05
ATE509096T1 (de) 2011-05-15
IL195831A0 (en) 2011-08-01
EP2030984A4 (en) 2009-08-26
US20130288363A1 (en) 2013-10-31
US20120115221A1 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
HK1128924A1 (en) Sparc-derived cancer rejection antigen peptide and pharmaceutical comprising the same sparc
TWI417103B (zh) Ｈｌａ-ａ＊１１０１限制性ｗｔ１胜肽及含有該限制性胜肽之醫藥組成物
WO2006090810A3 (en) Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
EP2189471A4 (en) PEPTIDE FOXM1 AND MEDICINAL AGENT COMPRISING SAME
EP2583976A3 (en) Peptide vaccines with SEQ ID NO: 210, 196, 202, 213, 214, 214 or 223 for cancers expressing tumor-associated antigens
EP2476698A3 (en) Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
EP2228072A4 (en) CANCER VACCINE COMPOSITION
EA201100586A1 (ru) Новая иммунотерапия против нескольких видов опухолей, включая нейрональные опухоли и опухоли головного мозга
EP1536009A4 (en) ANTIGEN PEPTIDE OF HLA-A24 RESTRICTED CANCER
JP2005516072A5 (zh)
RU2008109015A (ru) Глипикан-3 (gpc3)-производные антигенные пептиды, отторгающие опухоли, используемые для нla-a2-положительных пациентов, и фармацевтическая продукция, включающая их
CY1112867T1 (el) Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια
SG10201407944TA (en) Imp-3 oligopeptides and vaccines including the same
MX2011008763A (es) Peptidos foxm1 y vacunas que contienen los mismos.
MX2011007963A (es) Peptidos neil3 y vacunas que incluyen los mismos.
WO2005123760A3 (en) Treating cancer
ES2882827T3 (es) Péptido inductor de inmunidad derivado de HSP70
MX2009007261A (es) Vacuna de peptido foxp3.
BR112012025567A2 (pt) peptídeos de cdca5 e vacinas que incluem os mesmos
DK1536006T3 (da) Cancerantigener og anvendelse deraf
FI20050753A (fi) Uudet peptidit
MX2010005816A (es) Epítopos de péptido de stat3.
NZ592461A (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same
EP3208334A3 (en) Cdc45l peptides and vaccines including the same
MX2012006770A (es) Peptidos tmem22 y vacunas que incluyen los mismos.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230615